Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness

Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Martins, R. N., Rainey-Smith, S., Robertson, J., Rowe, C. C., Salvado, O., Doré, V., Villemagne, V. L., Snyder, P. J., Masters, C. L. & Maruff, P. (2017). Amyloid β–associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer S and Dementia Diagnosis Assessment and Disease Monitoring, 8 (1), pp.156-164. https://doi.org/10.1016/j.dadm.2017.05.006.

Access Status

Open Access

Abstract

INTRODUCTION: High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. METHOD: Cognition was measured over 72 months and compared between low (Aβ-) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. RESULTS: Compared to the Aβ- group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. DISCUSSION: Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.

Publisher Licence

CC BY-NC-ND

Publisher URL

https://doi.org/10.1016/j.dadm.2017.05.006

Collections

Florey Department of Neuroscience and Mental Health - Research Publications
Anatomy and Neuroscience - Research Publications
Business & Economics Collected Works - Research Publications
Medicine (Austin & Northern Health) - Research Publications
Minerva Elements Records
Psychiatry - Research Publications